Dual Effects of Sodium Butyrate on Hepatocellular Carcinoma Cells

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2012 Jan 10

PMID 22228088

Citations 13

Authors

Wenjun Jiang

Qiya Guo

Jun Wu

Bin Guo

Yingming Wang

Shenan Zhao

Huiling Lou

Xin Yu

Xinyu Mei

Chaoqun Wu

Shouyi Qiao

Yanhua Wu

Affiliations

Soon will be listed here.

Abstract

Sodium butyrate (NaBu), a histone deacetylase inhibitor, has been shown to inhibit cell growth, induce cell differentiation and apoptosis in multiple cell lines. In present study, we revealed the dual effects of NaBu in regulating hepatocellular carcinoma (HCC) cells. In two different HCC cell lines, SK-Hep1 and SMMC-7721, low concentrations of NaBu induced a significant increase in cell growth ratio and S-phase cell percentage, accompanied by a reduced p21 Cip1 expression at both mRNA and protein levels, while dissimilarly, high concentrations of NaBu inhibited cell growth and induced G1 arrest through up-regulation of p21 Cip1 and p27 Kip1 protein expression. The reduction of p45 Skp2 expression further indicated that the ubiquitin-mediated protein degradation might play a role in NaBu-induced up-regulation of p21 Cip1 and p27 Kip1. Moreover, the high concentration of NaBu was also able to trigger HCC cell apoptosis. Taken together, these results demonstrate the distinct effects of NaBu at different dosages. This finding may contribute to develop more effective tumor therapeutic protocols of NaBu in HCC.

Citing Articles

SWATH-MS insights on sodium butyrate effect on mAbs production and redox homeostasis in CHO cells.

Galli M, Liu L, Sim K, Kok Y, Wongtrakul-Kish K, Nguyen-Khuong T AMB Express. 2024; 14(1):140.

PMID: 39718710 PMC: 11668706. DOI: 10.1186/s13568-024-01807-z.

Gut-Liver-Pancreas Axis Crosstalk in Health and Disease: From the Role of Microbial Metabolites to Innovative Microbiota Manipulating Strategies.

Marroncini G, Naldi L, Martinelli S, Amedei A Biomedicines. 2024; 12(7).

PMID: 39061972 PMC: 11273695. DOI: 10.3390/biomedicines12071398.

The Emerging Role of the Microbiota in Breast Cancer Progression.

Bernardo G, Le Noci V, Di Modica M, Montanari E, Triulzi T, Pupa S Cells. 2023; 12(15).

PMID: 37566024 PMC: 10417285. DOI: 10.3390/cells12151945.

The Role of Gut Microbiome-Derived Short-Chain Fatty Acid Butyrate in Hepatobiliary Diseases.

Pant K, Venugopal S, Lorenzo Pisarello M, Gradilone S Am J Pathol. 2023; 193(10):1455-1467.

PMID: 37422149 PMC: 10548274. DOI: 10.1016/j.ajpath.2023.06.007.

Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas.

Manta A, Kazanas S, Karamaroudis S, Gogas H, Ziogas D Oncol Res. 2023; 30(5):211-219.

PMID: 37305348 PMC: 10207982. DOI: 10.32604/or.2022.026913.

References

Chopin V, Toillon R, Jouy N, Le Bourhis X . P21(WAF1/CIP1) is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells. Oncogene. 2004; 23(1):21-9. DOI: 10.1038/sj.onc.1207020. View

Saito H, Tada S, Ebinuma H, Tsunematsu S, Kagawa T, Kumagai N . Changes of antigen expression on human hepatoma cell lines caused by sodium butyrate, a differentiation inducer. J Gastroenterol. 1994; 29(6):733-9. DOI: 10.1007/BF02349279. View

Orchel A, Dzierzewicz Z, Parfiniewicz B, Weglarz L, Wilczok T . Butyrate-induced differentiation of colon cancer cells is PKC and JNK dependent. Dig Dis Sci. 2005; 50(3):490-8. DOI: 10.1007/s10620-005-2463-6. View

Prasad K . Butyric acid: a small fatty acid with diverse biological functions. Life Sci. 1980; 27(15):1351-8. DOI: 10.1016/0024-3205(80)90397-5. View

Archer S, Meng S, Shei A, Hodin R . p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci U S A. 1998; 95(12):6791-6. PMC: 22637. DOI: 10.1073/pnas.95.12.6791. View

Terao Y, Nishida J, Horiuchi S, Rong F, Ueoka Y, Matsuda T . Sodium butyrate induces growth arrest and senescence-like phenotypes in gynecologic cancer cells. Int J Cancer. 2001; 94(2):257-67. DOI: 10.1002/ijc.1448. View

Hung W, Chuang L . Sodium butyrate enhances STAT 1 expression in PLC/PRF/5 hepatoma cells and augments their responsiveness to interferon-alpha. Br J Cancer. 1999; 80(5-6):705-10. PMC: 2362280. DOI: 10.1038/sj.bjc.6690413. View

Wakabayashi K, Saito H, Ebinuma H, Saito Y, Takagi T, Nakamura M . Bcl-2 related proteins are dramatically induced at the early stage of differentiation in human liver cancer cells by a histone deacetylase inhibitor projecting an anti-apoptotic role during this period. Oncol Rep. 2000; 7(2):285-8. DOI: 10.3892/or.7.2.285. View

Saramaki A, Banwell C, Campbell M, Carlberg C . Regulation of the human p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor. Nucleic Acids Res. 2006; 34(2):543-54. PMC: 1351372. DOI: 10.1093/nar/gkj460. View

10.

Yamamoto H, Fujimoto J, Okamoto E, Furuyama J, Tamaoki T, Hashimoto-Tamaoki T . Suppression of growth of hepatocellular carcinoma by sodium butyrate in vitro and in vivo. Int J Cancer. 1998; 76(6):897-902. DOI: 10.1002/(sici)1097-0215(19980610)76:6<897::aid-ijc21>3.0.co;2-z. View

11.

Ogawa K, Yasumura S, Atarashi Y, Minemura M, Miyazaki T, Iwamoto M . Sodium butyrate enhances Fas-mediated apoptosis of human hepatoma cells. J Hepatol. 2004; 40(2):278-84. DOI: 10.1016/j.jhep.2003.09.021. View

12.

Saito H, Ebinuma H, Takahashi M, Kaneko F, Wakabayashi K, Nakamura M . Loss of butyrate-induced apoptosis in human hepatoma cell lines HCC-M and HCC-T having substantial Bcl-2 expression. Hepatology. 1998; 27(5):1233-40. DOI: 10.1002/hep.510270508. View

13.

Saito H, Kagawa T, Tada S, Tsunematsu S, Guevara F, Watanabe T . Effect of dexamethasone, dimethylsulfoxide and sodium butyrate on a human hepatoma cell line PLC/PRF/5. Cancer Biochem Biophys. 1992; 13(2):75-84. View

14.

Sung Y, Song Y, Lim S, Chung J, Lee G . Effect of sodium butyrate on the production, heterogeneity and biological activity of human thrombopoietin by recombinant Chinese hamster ovary cells. J Biotechnol. 2004; 112(3):323-35. DOI: 10.1016/j.jbiotec.2004.05.003. View

15.

Augeron C, Laboisse C . Emergence of permanently differentiated cell clones in a human colonic cancer cell line in culture after treatment with sodium butyrate. Cancer Res. 1984; 44(9):3961-9. View

16.

Giermasz A, Makowski M, Kozlowska E, Nowis D, Maj M, Jalili A . Potentiating antitumor effects of a combination therapy with lovastatin and butyrate in the Lewis lung carcinoma model in mice. Int J Cancer. 2002; 97(6):746-50. DOI: 10.1002/ijc.10119. View

17.

Saito H, Morizane T, Watanabe T, Kagawa T, Miyaguchi S, Kumagai N . Differentiating effect of sodium butyrate on human hepatoma cell lines PLC/PRF/5, HCC-M and HCC-T. Int J Cancer. 1991; 48(2):291-6. DOI: 10.1002/ijc.2910480223. View

18.

Wakabayashi K, Saito H, Kaneko F, Nakamoto N, Tada S, Hibi T . Gene expression associated with the decrease in malignant phenotype of human liver cancer cells following stimulation with a histone deacetylase inhibitor. Int J Oncol. 2004; 26(1):233-9. View

19.

Emanuele S, DAnneo A, Bellavia G, Vassallo B, Lauricella M, De Blasio A . Sodium butyrate induces apoptosis in human hepatoma cells by a mitochondria/caspase pathway, associated with degradation of beta-catenin, pRb and Bcl-XL. Eur J Cancer. 2004; 40(9):1441-52. DOI: 10.1016/j.ejca.2004.01.039. View

20.

Takimoto R, Kato J, Terui T, Takada K, Kuroiwa G, Wu J . Augmentation of antitumor effects of p53 gene therapy by combination with HDAC inhibitor. Cancer Biol Ther. 2005; 4(4):421-8. DOI: 10.4161/cbt.4.4.1620. View